PILL News and Press, Direxion Daily Pharmaceutical & Medical Bull 3X Shares From 12/09/23

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...

2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...

2023-11-22 02:15:00 ET Summary Q3 earnings season had many familiar refrains relative to the year’s first two quarters. One difference was a return to positive earnings growth for the first time since Q3 2022. Not unlike the first two quarters of the year, earnings for ...

2023-11-21 09:05:00 ET Summary A more volatile macroeconomic regime, alongside relatively high rates, may mean investors need to demand greater compensation for taking on equity risk; they can meet this higher performance bar by getting precise about targeted opportunities. The AI...

2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...

2023-11-14 05:40:00 ET Summary Healthcare stocks have underperformed the global market this year. Investors in healthcare stocks have been disappointed in 2023. Active investors can find attractively valued companies that benefit from durable business growth trends across the ...

2023-11-11 13:29:00 ET More on ETF weekly movers BOIL And Natural Gas: The Best Way To Profit LABU And LABD: Another Attractive Double-Short Pairs Trade Consider BOIL As Seasonality Supports A Natural Gas Rally UVXY, LABU and NAIL among weekly ETF movers ...

2023-11-03 03:30:00 ET Summary Following a strong first half of 2023, third quarter returns were more challenged across almost all asset classes. One outlier was high-yield debt, which often serves as a way to de-risk equity exposures when stocks are under pressure. Most year-...

2023-10-23 12:05:00 ET Summary U.S. corporate earnings have stagnated with the economy. We stay selective in stocks and harness mega forces like artificial intelligence as key profit centers. The 10-year U.S. Treasury yield hit 16-year highs near 5.0% last week, while U.S. stocks ...

2023-10-19 03:12:00 ET Summary Drugmakers don’t have to dominate a healthcare portfolio. Equity investors should cast a wide net across the sector to find innovation and growth. When pharmaceutical companies conduct tests on new drugs, they typically outsource clinical tria...